Genta Inc.'s ongoing bid to find a replacement partner for Genasense can only be helped by more positive news from its Phase III study testing the compound with chemotherapy against relapsed or refractory chronic lymphocytic leukemia. (BioWorld Today)

"NSCLC" might sound like a sports league to some, but the acronym has a much more dire meaning to physicians and their patients, who battle a disease yet to meet its match in the laboratory despite the best efforts of biotechnology firms.